jacek_glinka_mylan

Mylan hires president of European business

pharmafile | October 21, 2013 | Appointment | Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Mylan, glinka 

Mylan has announced that from December Jacek Glinka will be the president of its European business.

Glinka served as chief executive for the Polpharma Group from 2003 to 2006, and from 2009 to 2013. Under his leadership, Polpharma became the leader in the Polish market and one of the fastest growing pharma companies in the region. Glinka will report to Hal Korman, Mylan’s chief operating officer.

Mylan chief executive Heather Bresch said: “We are thrilled to welcome Jacek to Mylan. His exceptional track record leading Polpharma speaks for itself and we believe his deep experience in the region will contribute to Mylan’s continued success and growth in Europe.”

Advertisement

Glinka added: “I look forward to working with Mylan’s global and regional leaders to continue to maximize the power of the Mylan platform across the region and further solidify Mylan’s leadership positions in key markets. I also look forward to leveraging my expertise, particularly in the exciting Central and Eastern European markets, to further expand Mylan’s footprint.”

Prior to leading Polpharma, Glinka was a managing director at Spectra Services, where he oversaw a number of acquisitions and restructurings, including the acquisition and integration of Akrihin into Polpharma Group. He began his professional career as a strategic management consultant with firms including Deloitte & Touche and A.T. Kearney.

Related Content

Pfizer to pay $345 million in EpiPen lawsuit

Pfizer has reached a $345 million settlement over consumer claims they overpaid for EpiPens as …

Mylan reaches agreement with Aspen for their European thrombosis business

Mylan has announced an agreement to acquire the intellectual property and commercialisation rights to Aspen’s …

Mylan secures first FDA approval for generic version of Biogen’s Tecfidera following patent dispute

The FDA has approved its first generic of Biogen’s multiple sclerosis (MS) treatment Tecfidera, awarding …

The Gateway to Local Adoption Series

Latest content